Ignite Creation Date:
2024-05-06 @ 8:03 PM
Last Modification Date:
2024-10-26 @ 3:19 PM
Study NCT ID:
NCT06231017
Status:
RECRUITING
Last Update Posted:
2024-01-30
First Post:
2024-01-21
Brief Title:
Adebrelimab Plus Cetuximab and Chemotherapy for Patients With RASBRAF Wild-Type Unresectable Liver Metastases Colorectal Cancer
Sponsor:
The First Affiliated Hospital of Zhengzhou University
Organization:
The First Affiliated Hospital of Zhengzhou University
Study Overview
Official Title:
A Single-arm Open-label Phase Ⅱ Clinical Trial of Adebrelimab Plus Cetuximab and Chemotherapy for Patients With RASBRAF Wild-Type Unresectable Liver Metastases Colorectal Cancer
Status:
RECRUITING
Status Verified Date:
2024-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to observe and evaluate the efficacy and safety of adebrelimab plus cetuximab and chemotherapy for patients with RASBRAF wild-type unresectable liver metastases colorectal cancer
Detailed Description:
Colorectal cancer is the third largest malignant tumor in the world and a significant cause of cancer-related deaths The probability of simultaneous liver metastasis in colorectal cancer is about 25 and the proportion of liver metastasis occurring in the entire disease process is as high as 40 -50 It is of great clinical significance to transform the initial unresectable liver metastases of colorectal cancer into resectable ones to improve the overall survival rate and prognosis of colorectal cancer patients We designed a single-arm open phase II clinical trial of adebrelimab plus cetuximab and chemotherapy for patients with RASBRAF wild-type unresectable liver metastases colorectal cancer The purpose of this study is to observe and evaluate the efficacy and safety of adebrelimab plus cetuximab and chemotherapy for patients with RASBRAF wild-type unresectable liver metastases colorectal cancer
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None